Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

UNITY Biotechnology Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 03:40PM GMT
Release Date Price: $80.7 (-2.65%)
Ross Howard Weinreb
Goldman Sachs Group Inc., Research Division - Research Analyst

Great. So good morning, everybody, and welcome to Goldman Sachs' 40th Annual Healthcare Conference. My name is Ross Weinreb. I'm one of the biotech technology associates here, and it's my pleasure to introduce Keith Leonard, CEO and Chairman of UNITY Biotechnology.

Questions & Answers

Ross Howard Weinreb
Goldman Sachs Group Inc., Research Division - Research Analyst

So Keith, it's been about a year since your IPO. Can you walk us through some of the pipeline progress you guys have made thus far? And any incremental updates that we should be looking forward to over the next 6 months?

Keith R. Leonard
Unity Biotechnology, Inc. - Executive Chairman & CEO

Sure. So as many of you may know, UNITY is a company focused on extending health span. We do that by attacking specific diseases of aging, where our aim is to slow, halt or reverse those diseases of aging. The progress on the pipeline in that mission in the last year,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot